Opposes: the best-controlled evidence shows acetaminophen in pregnancy does not cause autism. Sibling comparisons of about 2.5 million Swedish children and a 2026 Lancet meta-analysis found no link, and a Danish study of 1.5 million children agreed.
Observational links can reflect the illnesses that lead mothers to take acetaminophen and the genes families share. When Swedish researchers compared siblings, the small association with autism disappeared, and a 2026 meta-analysis of sibling studies found none. A Danish study of more than 1.5 million children published in April 2026 also found no association.The core problem with observational studies here is confounding: the infections and pain that lead mothers to take acetaminophen, and the genes families share, may themselves be linked to autism. Comparing siblings, one exposed in the womb and one not, controls for much of this.
The largest such study covered about 2.5 million Swedish children. Without sibling control, use in pregnancy was tied to a marginally higher autism risk (hazard ratio 1.05). In matched full siblings the association vanished (hazard ratio 0.98), with no dose-response pattern, and the authors attributed earlier findings to familial confounding (Ahlqvist et al., JAMA 2024). A January 2026 meta-analysis in The Lancet Obstetrics, Gynaecology and Women's Health pooled sibling-comparison studies and found no association with autism (odds ratio 0.98), ADHD or intellectual disability, nor any among low-bias studies (Lancet meta-analysis). In April 2026 a Danish study of more than 1.5 million children, published in JAMA Pediatrics, also found no association, including after accounting for dose and trimester (CNN/Reuters).
Limits. No randomised trial exists, and none is likely for ethical reasons. Sibling designs have their own weaknesses, including relatively few discordant pairs and imperfect records of over-the-counter use. Very high or prolonged doses could carry a small risk that current studies cannot detect.